CRL vs XPER · rev $2.00B vs rev $448.1M
Charles River Laboratories (CRL) versus Xperi Corp (XPER) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Xperi Corp (XPER) is a software - application company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported XPER revenue for 2025-12-31 was $448.1M. Net income was -$56.3M. Revenue was down 9.2% from 2024-12-31 to 2025-12-31. XPER currently screens at market cap $367.8M.
CRL currently screens at market cap $7.78B. XPER currently screens at market cap $367.8M.
Not investment advice. Open the CRL and XPER stock pages for the full models.
Not investment advice.